Joint Guidelines for the Management of Interruption of Biologic Therapies for Elective Surgery in Adults and Children with Rheumatoid Arthritis, Psoriatic Arthritis, JIA and Ankylosing Spondylitis
(see Gastroenterology and Dermatology guidelines for their patients)

For Use in: Organisation-wide elective surgery preparation in patients receiving biologic drugs
By: All clinicians and surgical pre-assessment staff involved in preparing patients for elective surgery
For: Adults and Children with Rheumatological conditions requiring Biologic Therapy, who are undergoing elective surgical procedures
Division responsible for document: Medical Division (Including Emergency)
Key words: Biologics, Anti-TNF, Biosimilars, Rheumatoid Arthritis, arthritis, delayed healing, immunosuppression, infection, JIA, Psoriatic Arthritis, juvenile, risk

Name and job title of document author: Nicola Kerrigan, Specialist Nurse in Rheumatology
Name and job title of document author’s Line Manager: Karen Mills, Lead Specialist Nurse in Rheumatology

Supported by: Dr Tarnya Marshall - Consultant Rheumatologist and Clinical Director (NNUH), Prof Karl Gaffney - Consultant Rheumatologist, (NNUH), Dr Chetan Mukhtyar - Consultant Rheumatologist (NNUH), Dr Joegi Thomas - Consultant Rheumatologist (JPUH), Dr Anna Lipp - Consultant Anaesthetist (NNUH), Dr Kate Armon - Consultant Paediatric Rheumatologist (NNUH and CHUH), Samantha Sparrow - Orthopaedic Pharmacist (NNUH), Miranda Smith, Rheumatology Sister (QEHKL)

Assessed and approved by the: Clinical Guidelines Assessment Panel (CGAP)
Date of approval: 01 August 2019

Ratified by or reported as approved to (if applicable): Clinical Safety and Effectiveness Sub-Board
To be reviewed before: 01 May 2022
To be reviewed by: Nicola Kerrigan
Reference and / or Trust Docs ID No: JCG0030 - 1254
Version No: 4.1
Description of changes: QEH header added – document now a 3 Trust guideline
Compliance links: (is there any NICE related to guidance) No
Joint Guidelines for the Management of Interruption of Biologic Therapies for Elective Surgery in Adults and Children with Rheumatoid Arthritis, Psoriatic Arthritis, JIA and Ankylosing Spondylitis
(see Gastroenterology and Dermatology guidelines for their patients)

<table>
<thead>
<tr>
<th>If Yes - does the strategy/policy deviate from the recommendations of NICE? If so why?</th>
<th>N/A</th>
</tr>
</thead>
</table>
Therapies Discussed in this Guideline including at the time of publication (others may be available in the future)

<table>
<thead>
<tr>
<th>Class/Target</th>
<th>Trade Name</th>
<th>Generic Name</th>
<th>Biosimilar Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-TNF</td>
<td>Enbrel</td>
<td>Etanercept</td>
<td>Benepali, Erelzi</td>
</tr>
<tr>
<td></td>
<td>Humira</td>
<td>Adalimumab</td>
<td>Amgevita, Imraldi</td>
</tr>
<tr>
<td></td>
<td>Remicade</td>
<td>Infliximab</td>
<td>Remsima, Inflectra</td>
</tr>
<tr>
<td></td>
<td>Cimzia</td>
<td>Certolizumab</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Simponi</td>
<td>Golimumab</td>
<td></td>
</tr>
<tr>
<td>B-cell Depletor</td>
<td>Mabthera</td>
<td>Rituximab</td>
<td>Rixathon,Truxima</td>
</tr>
<tr>
<td>IL 6</td>
<td>Roactemra</td>
<td>Tocilizumab</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sarilumab</td>
<td>Kevzara</td>
<td></td>
</tr>
<tr>
<td>IL 17</td>
<td>Cosentyx</td>
<td>Secukinumab</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Taltz</td>
<td>Ixekizumab</td>
<td></td>
</tr>
<tr>
<td>T-cell Depletor</td>
<td>Ocrenia</td>
<td>Abatacept</td>
<td></td>
</tr>
<tr>
<td>IL 12 / IL 13</td>
<td>Stelara</td>
<td>Ustekinumab</td>
<td></td>
</tr>
<tr>
<td>JAK Inhibitor</td>
<td>Olumiant</td>
<td>Baracitinib</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Xeljanz</td>
<td>Tofacitinib</td>
<td></td>
</tr>
<tr>
<td>Immune Modulator</td>
<td>Otezla</td>
<td>Apremilast</td>
<td></td>
</tr>
</tbody>
</table>
For the purpose of this table, we are using generic names only

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosing Interval</th>
<th>Period in which surgery should be scheduled (relative to last biologic dose administered)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Etanercept</td>
<td>Weekly or twice weekly</td>
<td>Week 2</td>
</tr>
<tr>
<td>Adalimumab</td>
<td>Every 2 weeks</td>
<td>Week 3</td>
</tr>
<tr>
<td>Infliximab</td>
<td>Every 4, 6 or 8 weeks</td>
<td>Week 5, 7 or 9</td>
</tr>
<tr>
<td>Certolizumab</td>
<td>Every 2 weeks</td>
<td>Week 3</td>
</tr>
<tr>
<td>Golimumab</td>
<td>Every 4 weeks</td>
<td>Week 5</td>
</tr>
<tr>
<td>Rituximab</td>
<td>Two doses 2 weeks apart, no more frequent than every 6 months</td>
<td>Months 4-7</td>
</tr>
<tr>
<td>Tocilizumab i.v.</td>
<td>Every 4 weeks</td>
<td>Week 5</td>
</tr>
<tr>
<td>Tocilizumab s.c.</td>
<td>Every week</td>
<td>Week 3</td>
</tr>
<tr>
<td>Sarilimumab</td>
<td>Every 2 weeks</td>
<td>Week 4</td>
</tr>
<tr>
<td>Secukinumab</td>
<td>Monthly s/c</td>
<td>12 weeks</td>
</tr>
<tr>
<td>Ixekizumab</td>
<td>Monthly s/c</td>
<td>Week 10</td>
</tr>
<tr>
<td>Abatacept i.v.</td>
<td>Monthly i.v.</td>
<td>Week 5</td>
</tr>
<tr>
<td>Abatacept s.c.</td>
<td>Weekly s.c.</td>
<td>Week 2</td>
</tr>
<tr>
<td>Ustekinumab</td>
<td>Every 12 weeks</td>
<td>Week 13</td>
</tr>
<tr>
<td>Baracitinib</td>
<td>Daily oral dose</td>
<td>Stop dosing 2 days prior to surgery</td>
</tr>
<tr>
<td>Tofacitinib</td>
<td>Twice daily oral dose</td>
<td>Stop dosing 2 days prior to surgery</td>
</tr>
<tr>
<td>Apremilast</td>
<td>Daily oral dose</td>
<td>Stop dosing 2 days prior to surgery</td>
</tr>
</tbody>
</table>

**Recommence Biologics once Surgeon is happy with the wound and no other signs of infection, e.g. on antibiotics**

**Objective**
To enhance patient safety peri-operatively in terms of reducing risk of infection and promoting optimal wound healing

Rationale

Biologic Therapies are now widely used for the treatment Rheumatological conditions including rheumatoid arthritis, psoriatic arthritis, JIA and ankylosing spondylitis

Patients with rheumatological diseases have unique surgical risk factors, such as the exposure to disease modifying anti-rheumatic drugs (DMARDS) and corticosteroids that, in addition to their underlying disease, could predispose them to infections.

Tumour Necrosis Factor (TNF) mediates inflammation and modulates cellular immune responses. TNF inhibitors may therefore affect host defences against infection. This is thought to pose a risk for the development of postoperative infections and healing complications in patients with rheumatological diseases undergoing surgery.

The British Society of Rheumatology’s (BSR) 2018 statement on the safety of biologic therapies encourages consideration of the risks and benefits of pausing biologics peri-operatively. (1)

Staff involved in preparing patients for elective surgery need to be aware of the rationale for pausing biologic therapy for Rheumatology patients and the specific time scales involved for each therapy. For concerns regarding individual cases, please contact the patient’s rheumatology consultant for advice.

New patients starting on biologic therapies in the Rheumatology Department are given in depth counselling about the risks of infection generally and how to manage their therapy in the event of elective surgery.

Rheumatology biologics patients have a PAS alert to help identify that they are taking biologic therapies and the need to stop these agents prior to elective surgery. Patients are also given an alert card to remind them to stop their therapies prior to surgery. None of these mechanisms is failsafe however.

Broad recommendations

BSR guidance suggests that for most biologics, allow one dosing interval to elapse prior to surgery.

For higher risk procedures, consideration should be given to stopping 3 - 5 x half-lives for the relevant drug before surgery.
Biologic therapy should not be restarted after surgery until there is good wound healing (typically around 14 days), all sutures and staples are out, no evidence of infection, however subtle (2), and the surgeon is happy with the wound.

For **clean surgical procedures**, (i.e. arthroscopy) washout = 3 x half life

For **high infection risk procedures**, (i.e. GI tract surgery) washout = 5 x half life

**Stop** biologics prior to dental extractions

**Stop** biologics prior to biopsies resulting in open granulation tissue

**Do not stop** biologics prior to endoscopy, cystoscopy, liver/kidney biopsy, lymph node biopsy or punch biopsy

For bloodless procedures (such as cataract surgery) we would not advise routinely stopping biologics.

**Note:** Patients may flare when their biologic drug is stopped, and surgical outcomes may be adversely affected in a patient with systemic disease. If steroids are used to suppress flares whilst withholding the biologic drug, they may have an even greater adverse effect on surgical outcomes. Please contact the patient’s Rheumatology consultant or the Biologics Specialist Nurses (x3786) for advice.

**Advice regarding stopping DMARDS (ie Methotrexate) prior to Elective Surgery**

We do not advocate stopping traditional DMARDS (methotrexate, leflunomide, sulphasalazine, hydroxychloroquine, ciclosporin, mycophenolate mofetil) perioperatively. However if you have specific concerns about individual cases, please contact the patient’s Rheumatology consultant.

**Scope**

The advice given in this guideline extends to the use of biosimilar biologic products. It also covers JAK inhibitors (ie Baricitinib) and Apremilast (immune modulator) which are not biologics, but are new agents. Our experience of using them is limited and we need further information regarding their risks in relation to elective surgery. Therefore, for safety reasons, we are currently recommending stopping these agents prior to surgery pending further safety data.

**Clinical audit standards**

To ensure that this document is compliant with the above standards, the following monitoring processes will be undertaken:
Clinical audit will be carried out at a regular interval.
The aim of the audit is to ensure that:

‘All patients currently treated on biologics have appropriate interruption in treatment when undergoing surgery’

The audit will require information to be collected on:

- Which biologic treatment patient is taking
- Details of type of surgery
- Outcomes of the surgery, i.e. any post-operative infection
- Details of interruption in biologic treatment, i.e. stop and start dates

This audit may require use of patient electronic letters, medical notes and patient questionnaires. Results of audits will be shared with the Clinical Director and presented and discussed at Clinical Governance meetings.

Summary of development and consultation process undertaken before registration and dissemination

The authors listed above reviewed this guideline on behalf of the MDT in the Rheumatology Department across 3 Trusts, who have agreed the final content.

During its development it was / has been circulated for comment to:

Nurse Specialists, QEHKL
Rheumatology Consultants
Rheumatology Registrars
Rheumatology Specialist Nurses
Dr Joegi Thomas, Consultant Rheumatologist JPUH
Colin Green Pharmacist
Dr Anna Lipp, Consultant Anaesthetist
Pre-op Assessment Nurses
Orthopaedic surgeon
General surgeon
Plastics surgeon
Paediatric Rheumatology team
Joint Guidelines for the Management of Interruption of Biologic Therapies for Elective Surgery in Adults and Children with Rheumatoid Arthritis, Psoriatic Arthritis, JIA and Ankylosing Spondylitis
(see Gastroenterology and Dermatology guidelines for their patients)

References


3. SmPC for Secukinumab (Cosentyx) (Internet). Date of revision of text 23/10/2018
   Available from Novartis.customercare@novartis.com

4. SmPC for Ixekizumab (Taltz) [Internet] date of revision of text 24 May 2018.
   Available from www.lilly.co.uk

5. SmPC for Baricitinib (Olumiant) (Internet) Date of revision of text 27/09/18
   Available from www.lilly.co.uk

6. SmPC for Tofacitinib (Xeljanz) (Internet) Date of revision of text 11/2018
   Available from www.pfizermedicalinformation.co.uk

7. SmPC for Sarilumab (Kevzara) (Internet) Date of revision of text 24/08/2017
   Available from uk-medicalinformation@sanofi.com

8. SmPC for Apremilast (Otezla) (Internet) Date of revision of text 19/12/2018
   Available from medinfo.uk.ire@celgene.com